COLUMBUS, Ohio, July 18, 2016 /PRNewswire/ -- On Tuesday, July 12, 2016, ProclaRx, a biotechnology
Logo - http://photos.prnewswire.com/prnh/20160715/390122LOGO
The evening event was held at the home of Karl O. Elderkin, the Managing Partner at Athenian Venture Partners. The festivities were kicked off by Ohio University President, Dr. Roderick J. McDavis, with a formal presentation on the importance of entrepreneurship, commercialization of science, and the important role the community plays in advancing technology. ProclaRx CEO, Dr. Joseph D. Kittle, Jr., presented the company to the audience. Other featured presenters and notable attendees included Chris Gerig, Attorney at Gerig and Gerig; Debbie Phillips Bower, Owner of RE/MAX Premier Choice; George K. Richards, President of Capital Drugs; Tim O'Dell, CEO of CF Bank; Bob Milbourne, President of RHM Advisors; John Kopchick, PhD, Distinguished Professor of Molecular Biology at Ohio University; Jack Ellis, Emeritus Chief Executive Officer and Executive Director of The Ohio University Foundation, Ohio University; and Jim Sergi, President of CSSi LifeSciences™.
"The outpouring of support from Ohio University, the Athens Innovation Center and community, and Athenian Ventures at Tuesday's event was greatly appreciated," said Nick Henderson, Chairman, ProclaRx. "ProclaRx is hopeful to one day bring this game-changing technology to market, which could potentially benefit hundreds of thousands of people and children suffering from chronic bacterial infections."
ProclaRx's technology is envisioned to address unmet needs in patients suffering from not only ear infections, but also chronic sinusitis. The treatment is intended to disrupt and clear bacterial biofilm infections.
CSSi LifeSciences™ has been partnering with ProclaRx over the past year. "We are very excited to collaborate with the ProclaRx team and recognize the importance these treatments of recurrent infections may one day offer to patients," said Jim Sergi, President, CSSi LifeSciences™. "We strongly believe that ProclaRx is going to continue making great strides in the industry and beyond." During the event, Jim discussed the clinical and regulatory pathway for commercialization of the ProclaRx technology.
Established in 2014, ProclaRx and its staff of experienced scientists are committed to eliminating the causes of countless chronic and recurrent human infections. The Columbus-based company prides itself on developing and commercializing anti-infective technologies, with the goal of eliminating biofilms and helping cure diseases.With $6.5 million invested to-date, ProclaRx is seeking additional strategic partners to help further its continued efforts to develop multiple innovative therapeutics for patients suffering from serious bacterial infections.
To learn more about ProclaRx, please visit www.proclarx.com. If you are interested in supporting ProclaRx's efforts, please contact Nick Henderson for more information at firstname.lastname@example.org.
About ProclaRx:ProclaRx is a biotechnology company developing innovative therapeutics for patients suffering from serious bacterial infections. ProclaRx has a breakthrough discovery that inhibits and prevents bacterial biofilms. Lead indications include advanced wound care, chronic suppurative otitis media, and CVID sinusitis. Visit www.proclarx.com, call 949-302-2165, or email email@example.com.
Media Contacts:Courtney GaddiPublic Relations & Marketing CoordinatorCSSi(443) 308-5831Email
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/proclarx-hosts-networking-event-to-raise-awareness-of-its-groundbreaking-anti-infective-technology-300299579.html
Subscribe to our Free Newsletters!
Blood groups are of four important groups determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All